Concurrent homozygous sickle‐cell disease and severe haemophilia A: Thromboelastography profiles by Zaidi, Ahmar U. et al.
e124  |     LETTERS TO THE EDITOR
 
Received: 13 August 2018  |  Revised: 12 December 2018  |  Accepted: 16 January 2019
DOI: 10.1111/hae.13692
Concurrent homozygous sickle‐cell disease and severe 
haemophilia A: Thromboelastography profiles
Sickle‐cell disease (SCD) is an inherited chronic haemolytic anaemia 
that is characterized by unpredictable episodes of pain and wide‐
spread organ damage.1 Our understanding of the pathophysiology 
of SCD has expanded tremendously beyond the polymerization of 
sickle haemoglobin. It is now apparent that the heterogeneity in 
this monogenic disease is driven by a multitude of factors, ranging 
from variations in neutrophils, endothelium and platelet activation, 
and the coagulation cascade.2 Thrombotic contribution to vaso‐oc‐
clusion is involved in many of the complications and comorbidities 
associated with SCD. Although trials targeting platelets and coag‐
ulation in SCD have largely failed, the role of platelets and coag‐
ulation proteins in sickle‐cell disease continues to be a vigorous 
area of study. The thromboelastograph (TEG) is an instrument that 
generates a profile of changes in elasticity during whole‐blood co‐
agulation.3 The use of TEG as a tool to study coagulation defects 
has utility in several clinical settings.3 Additionally, sickle‐cell trait 
and disease patients demonstrate a hypercoagulable state in TEG 
profiles in several studies.4,5
The combination of SCD and haemophilia A has been reported twice 
in the medical literature. Glenn et al reported the case of a thirty‐year‐
old man with SCD and mild haemophilia A who was treated with DDAVP 
for blunt abdominal trauma.6 Dhiman et al reported a case of sickle‐beta 
thalassaemia with severe haemophilia A discovered incidentally after a 
dental procedure.7 Neither of these reports describe a longitudinal ac‐
count of the patient. We describe a sibling pair with haemoglobin SS 
disease and severe haemophilia A, their clinical history and our use of 
the TEG to identify the state of whole‐blood coagulation in this entity.
Sibling A is a 26‐year‐old African American man with the fol‐
lowing clinical profile: baseline haemoglobin electrophoresis of HbS 
78.6%, HbA2 2.9% and HbF 18.5%, factor VIII activity <1%, 16 pain 
admissions, 7 bleeding admissions, no stroke and not on chronic 
transfusions. Sibling B is a 14‐year‐old African American boy with 
the following clinical profile: baseline haemoglobin electrophoresis 
of HbS 90.9%, HbA2 3.2% and HbF 5.9%, factor VIII activity <1%, 
3 pain admissions, 5 bleeding admissions, intracranial haemorrhage 
after trauma and on chronic transfusions since that incident (trau‐
matic event occurred after the completion of the studies reported 
here). Neither sibling was on hydroxyurea, and both subjects were 
on prophylactic treatment with factor VIII replacement products.
Blood for TEG was drawn in the steady state for both patients, 
defined as no illness or pain in the preceding two weeks. We ob‐
tained TEG after a 72‐hour washout period from FVIII on both pa‐
tients as part of a baseline evaluation we do on all our patients with 
haemophilia. Citrated whole‐blood (340 µL) samples were activated 
using 20 µL of human tissue factor dilution. The use of tissue factor 
is based on our centre's established normal ranges for the TEG with 
a tissue factor control. The sample was recalcified using 20 µL CaCl2. 
The TEG parameters were then compared to a set of 30 patients with 
severe haemophilia A alone (including 2 half‐siblings of Sibling A and 
Sibling B) and a small cohort (n = 8) of HbSS patients in steady state 
in different studies at our institution. TEG parameters such as R time 
(clotting time), angle (rate of clot formation), maximum amplitude and 
maximum rate of thrombus generation (MRTG: the first derivative of 
the thromboelastographic curve can be plotted as a curve and re‐
flects the rate of fibrin generation; from this curve, the maximum rate 
of thrombus generation is derived along with the time taken to reach 
the MRTG (TMRTG)3) were compared. The mean values obtained 
are listed in Table 1. Figure 1 depicts the MRTG curves of Siblings A 
and B and representative patients with severe haemophilia A alone 
(half‐sibs 1 and 2) and HbSS disease alone. Thrombin generation was 
also assessed in the patients as part of a previous study (unpublished) 
in all of these patients, as described by Dargaud et al.8 Thrombin 
generation parameters analysed were lag time, peak height (peak), 
endogenous thrombin potential (ETP) and time to peak (Table 1). 
Since the TEG is affected by haemoglobin and platelet count, being 
a whole‐blood assay, we have presented the mean blood counts in‐
cluding WBC, haemoglobin and platelet counts for each of the groups 
in Table 1.
The TEG in patients with concurrent severe haemophilia A and 
homozygous HbSS shows an enhanced clotting potential com‐
pared to patients with severe haemophilia A alone. We postulate 
that the differences noted on the TEG tracing and MRTG curves 
in Siblings A and B may potentially be explained by the differ‐
ences in the HbF level. Sibling A has a higher HbF level, as seen 
with patients on hydroxyurea, and has a TEG profile that more 
closely resembles SHA, and conversely, Sibling B has a lower HbF 
level and has a TEG profile more closely resembling HbSS. When 
compared to patients with homozygous HbSS alone, they seem 
to have a lower thrombogenic potential, indicating that the two 
concurrent diagnoses may, in these patients, provide a beneficial 
balance between bleeding and thrombotic risks. The repeated 
cycles of erythrocyte sickling result in increased phosphati‐
dylserine on surface of sickled erythrocytes.9 Published litera‐
ture on the effect of foetal haemoglobin in thrombin generation 
suggests that elevated levels may impede exposure of phospha‐
tidylserine (PS) on the RBC membrane. The effect seen in this 
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sibling pair, Sibling A more than Sibling B, may be the result of 
the negation of PS exposure on the membrane, which results in 
loss of a “docking site” for haemostatic proteins on the phos‐
pholipid bilayer. Furthermore, the data on HbSS patients having 
increased factor VIII and von Willebrand factor activity are clear. 
Our sibling pair, though severe haemophilia A patients, have a 
mild phenotype. It is possible that the increased von Willebrand 
factor may be increasing the half‐life of infused factor VIII and 
decreasing bleeding. In HbSS patients, the combination of de‐
creased protein C and S10 with increased factor VIII, increased 
platelet activation and platelet‐white blood cell aggregation con‐
tributes to vaso‐occlusion. As shown in our sibling pair, this may 
be reflected in the TEG as short R time and, in its first derivative 
curve, increased rate of thrombin generation.
In summary, in patients with haemophilia A, the feedback loop 
causing a burst in thrombin generation is subdued given the low 
levels of factor VIII leading to a decreased production of thrombin 
as well as a fibrin clot that is vulnerable to fibrinolysis. In patients 
with sickle‐cell disease, a combination of increased red cell adhe‐
sion, platelet activation and increased tissue factor may result in in‐
creased thrombin generation. Here, we show a measurable change 
in whole‐blood coagulation in a sibling pair with the co‐inheritance 
of these two severe diseases that have distinct effects on the coag‐
ulation system.
TA B L E  1   Mean values of TEG parameters, thrombin generation profiles and blood counts
HbSS alone (n = 8)
HbSS with severe haemophilia A 
(n = 2) Severe haemophilia A (n = 30) Controls (n = 19)
TEG parameters
R time (min) 4.6 19.5 21.7 7.4
Angle (deg) 76.6 50.5 39.4 62.9
MA (mm) 73.1 68.2 59 62.1
MRTG (mm/100 s) 17.6 9.4 10.6 21.1
Thrombin generation data
Lag time (min) 2.35 2.45 4.91 4.20
ETP 576 795 785 1052
Peak (mm) 186.2 95.8 52 220
Time to peak 4.2 6.9 14.5 7.0
Complete blood count
White blood cell count 10.5 14.1 5.8 6.2
Haemoglobin 8.2 7.8 13.3 13.7
Platelets 353 311 247 297
F I G U R E  1   MRTG in varying clinical scenarios
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Factor IX inhibitors: Clinical and laboratory profiles of two 
patients with severe haemophilia B
Development of alloantibodies (inhibitors) to exogenous factor IX 
(FIX) protein in patients with severe haemophilia B (SHB) occurs 
in approximately 3%‐5% patients. Historically, immune tolerance 
induction (ITI) has been poorly effective for FIX inhibitors, with a 
success rate of just 15%‐30%.1 This stands in stark contrast to FVIII 
inhibitors where ITI success is generally reported at 75%‐80%. 
Additionally, planned attempts at ITI for FIX inhibitors may be ham‐
pered by allergic reactions to FIX containing products and may re‐
quire desensitization to FIX.2
Although still not well understood, pathophysiology of FVIII in‐
hibitors has received greater focus due to higher event frequency, 
with characterization of genetics and HLA‐type risk factors as well 
